Clinical trial · Observational
Biomarkers of Pancreatic Cancer and New Way to Detection
Identification of AREG for the Detection of Pancreatic Cancer By Biosensor
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Amphoteric regulatory protein (AREG), a member of epidermal growth factor (EGF) family, is expressed in many tumors.Our study confirmed that the expression of AREG in the serum of patients with pancreatic cancer is significantly higher than that of patients with benign pancreatic diseases and healthy people, which is expected to become a new early serum marker of pancreatic cancer. The serum concentration of AREG was detected by traditional ELISA and compared with CA-199, which was a conventional tumor marker of pancreatic cancer. Next, we compare the advantages of using sensor to detect AREG compared with ELISA.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| diagnosis of pancreatic cancer | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with pancreatic cancer
- description
- Patients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging manual.
- interventionNames
- Diagnostic Test: diagnosis of pancreatic cancer
- label
- Healthy Control
- description
- healthy controls had no history of benign pancreatic diseases and other benign and malignant tumors.
- interventionNames
- Diagnostic Test: diagnosis of pancreatic cancer
Primary outcomes (1)
- measure
- Diagnosis of Pancreatic Cancer
- timeFrame
- through study completion, an average of 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * The healthy control group had no history of benign pancreatic diseases and other benign and malignant tumors. * Patients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging manual. Exclusion Criteria: * Uncontrolled active infection. * Acute or chronic pancreatitis. * It is accompanied by other uncontrolled malignant tumors. * Any other uncontrolled active disease that prevents participation in the trial. * Having a history of mental illness that is difficult to control. * In the opinion of the investigator, the presence of medical or psychiatric history or laboratory abnormalities may increase the risk associated with participation in the study or the administration of the study drug, or may interfere with the interpretation of the results.
References
Publications (0)
Data not yet available